Oasmia Pharmaceutical Ab (0N4A)
LSE
Oasmia Pharmaceutical AB (publ) Interim report for the period May 2017 – January 2018 Commercial focus and lower cost base THIRD QUARTER November 1, 2017 – January 31, 2018 Consolidated net...
Oasmia Pharmaceutical’s Docecal program achieves significant development milestone Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 600 | 5.2065 | DE |
4 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 779 | 5.2065 | DE |
12 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 232 | 5.2065 | DE |
26 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 104 | 5.2065 | DE |
52 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 176 | 5.2065 | DE |
156 | 0 | 0 | 5.2065 | 5.2065 | 5.2065 | 2213 | 5.2065 | DE |
260 | 0.0995 | 1.94830624633 | 5.107 | 11.435 | 4.603 | 3879 | 5.49755144 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.